Only a few months after its impressive Nasdaq debut, antiviral firm Chimerix Inc. started dosing in its Phase III SUPPRESS trial testing oral nucleotide analogue lipid-conjugate brincidofovir (CMX001) for the prevention of cytomegalovirus (CMV) infection in hematopoietic cell transplant recipients.